JP2019514883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514883A5 JP2019514883A5 JP2018555281A JP2018555281A JP2019514883A5 JP 2019514883 A5 JP2019514883 A5 JP 2019514883A5 JP 2018555281 A JP2018555281 A JP 2018555281A JP 2018555281 A JP2018555281 A JP 2018555281A JP 2019514883 A5 JP2019514883 A5 JP 2019514883A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- disease
- independently
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 230000001588 bifunctional effect Effects 0.000 claims description 46
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 14
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims description 11
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010062038 Lip neoplasm Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000006721 lip cancer Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 210000004788 neurological cell Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 0 **c1c(C(N([C@](CCC(N2)=N)C2=*)C2=O)=*)c2ccc1 Chemical compound **c1c(C(N([C@](CCC(N2)=N)C2=*)C2=O)=*)c2ccc1 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326571P | 2016-04-22 | 2016-04-22 | |
| US62/326,571 | 2016-04-22 | ||
| PCT/US2017/028941 WO2017185031A1 (en) | 2016-04-22 | 2017-04-21 | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514883A JP2019514883A (ja) | 2019-06-06 |
| JP2019514883A5 true JP2019514883A5 (enExample) | 2020-05-28 |
| JP6921115B2 JP6921115B2 (ja) | 2021-08-18 |
Family
ID=60116458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555281A Active JP6921115B2 (ja) | 2016-04-22 | 2017-04-21 | サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10865204B2 (enExample) |
| EP (1) | EP3445765A4 (enExample) |
| JP (1) | JP6921115B2 (enExample) |
| CN (1) | CN109071552B (enExample) |
| AU (1) | AU2017254708B2 (enExample) |
| CA (1) | CA3018434A1 (enExample) |
| WO (1) | WO2017185031A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017254702B2 (en) * | 2016-04-22 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| LT3660004T (lt) * | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| AU2017348322B8 (en) * | 2016-10-28 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
| AU2017370694A1 (en) * | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| CN109516989B (zh) * | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| AU2019222652B2 (en) * | 2018-02-13 | 2021-09-02 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
| KR20200131246A (ko) | 2018-02-15 | 2020-11-23 | 누베이션 바이오 인크. | 키나제 억제제로서의 헤테로시클릭 화합물 |
| US20210261538A1 (en) * | 2018-02-22 | 2021-08-26 | Icahn School Of Medicine At Mount Sinai | Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use |
| WO2019173516A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| CN118754858A (zh) | 2018-03-26 | 2024-10-11 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US12226424B2 (en) | 2018-04-09 | 2025-02-18 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| JP2021529807A (ja) * | 2018-07-05 | 2021-11-04 | アイカーン スクール オブ メディスン アット マウント シナイ | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 |
| WO2020023480A1 (en) * | 2018-07-23 | 2020-01-30 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| WO2020092662A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| CN113423701A (zh) | 2018-11-13 | 2021-09-21 | 拜欧斯瑞克斯公司 | 取代的异吲哚啉酮 |
| US12582641B2 (en) | 2019-02-25 | 2026-03-24 | Shanghaitech University | Sulfur-containing compound based on glutarimide skeleton and application thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| KR20220004978A (ko) * | 2019-03-28 | 2022-01-12 | 에싸 파마 아이엔씨. | 단백질 분해 표적 키메라 리간드로서 사용하기 위한 안드로겐 수용체 조절제 및 방법 |
| EP3947368B1 (en) * | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| AU2020270908B2 (en) * | 2019-04-09 | 2025-09-25 | Beth Israel Deaconess Medical Center, Inc. | Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use |
| AU2020263390B2 (en) * | 2019-04-23 | 2026-01-08 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| US12465648B2 (en) | 2019-05-06 | 2025-11-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of HPK1 |
| CA3142713A1 (en) | 2019-06-03 | 2020-12-10 | Regents Of The University Of Minnesota | Compounds that degrade kinases and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
| TWI769382B (zh) * | 2019-06-21 | 2022-07-01 | 長庚大學 | 利博西林用於製備治療罹患磷酸二酯酶４介導疾病的患者的醫藥組合物及用途 |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN112321566B (zh) | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| ES2980575T3 (es) | 2019-12-18 | 2024-10-02 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
| WO2021185291A1 (zh) * | 2020-03-17 | 2021-09-23 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
| JP7857232B2 (ja) * | 2020-05-06 | 2026-05-12 | ニューリックス セラピューティクス，インコーポレイテッド | 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 |
| EP4146642A1 (en) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN111909155B (zh) * | 2020-08-21 | 2022-10-18 | 东莞理工学院 | 蛋白水解靶向嵌合体、提高其口服生物利用度的前药分子及应用 |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114349738B (zh) * | 2020-10-14 | 2023-05-05 | 清华大学 | 一类靶向降解cdk2的小分子缀合物及其应用 |
| KR20230130179A (ko) * | 2020-12-09 | 2023-09-11 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 그 용도 |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| CR20230614A (es) | 2021-06-03 | 2024-02-01 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos |
| MX2024004525A (es) * | 2021-10-14 | 2024-05-24 | Cullgen Shanghai Inc | Proteinas modificadas y degradadores de proteinas. |
| WO2023178130A1 (en) * | 2022-03-16 | 2023-09-21 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications |
| WO2023207875A1 (en) * | 2022-04-25 | 2023-11-02 | Onquality Pharmaceuticals China Ltd. | Cdk inhibitors, pharmaceutical compositions, and therapeutic applications |
| CN115364100B (zh) * | 2022-08-25 | 2023-08-29 | 杭州天玑济世生物科技有限公司 | Ly2835219作为线粒体自噬诱导剂的用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024083257A1 (zh) * | 2022-10-21 | 2024-04-25 | 上海领泰生物医药科技有限公司 | Sos1蛋白降解剂及其应用 |
| CN121358732A (zh) * | 2023-03-07 | 2026-01-16 | 睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025222132A1 (en) * | 2024-04-19 | 2025-10-23 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2025231380A1 (en) * | 2024-05-02 | 2025-11-06 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and methods of use thereof |
| WO2026067249A1 (en) * | 2024-09-29 | 2026-04-02 | K2 Medicines (Nanjing) Co., Ltd. | Cdk4 or cdk4/6 dual degrader and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE314370T1 (de) * | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| EA019094B1 (ru) * | 2008-08-22 | 2014-01-30 | Новартис Аг | Пирролопиримидины и их применение |
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| CN119591582A (zh) * | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| WO2016015604A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6921114B2 (ja) * | 2016-04-22 | 2021-08-18 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ８（ｃｄｋ８）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ８の分解および使用法 |
| WO2020023480A1 (en) * | 2018-07-23 | 2020-01-30 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
-
2017
- 2017-04-21 WO PCT/US2017/028941 patent/WO2017185031A1/en not_active Ceased
- 2017-04-21 CN CN201780024853.0A patent/CN109071552B/zh active Active
- 2017-04-21 US US16/094,098 patent/US10865204B2/en active Active
- 2017-04-21 JP JP2018555281A patent/JP6921115B2/ja active Active
- 2017-04-21 EP EP17786755.3A patent/EP3445765A4/en active Pending
- 2017-04-21 CA CA3018434A patent/CA3018434A1/en active Pending
- 2017-04-21 AU AU2017254708A patent/AU2017254708B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514882A5 (enExample) | ||
| JP2019514876A5 (enExample) | ||
| JP2019519476A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| JP2022547952A5 (enExample) | ||
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP2019535744A5 (enExample) | ||
| JP2023530231A5 (enExample) | ||
| JP2022527114A5 (enExample) | ||
| JP7371221B2 (ja) | Ｉｒａｋ４キナーゼ阻害剤及びその調製方法 | |
| JP2019535746A5 (enExample) | ||
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| JP2019524883A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2018515490A5 (enExample) | ||
| JP2013525363A5 (enExample) | ||
| JP2019510801A5 (enExample) | ||
| JP2024505571A5 (enExample) | ||
| JP2010509284A5 (enExample) | ||
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| JP2017532360A5 (enExample) | ||
| KR102142797B1 (ko) | 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도 |